On September 30, CANSINOBIO rose 5.92% in regular trading, trading at HK$34.64/share, with turnover of HK$42.29 million. The stock extended its post-holiday rebound as the mRNA personalized therapeutic cancer vaccine cooperation theme continued to attract market attention.

On the news front, CANSINOBIO previously announced that its subsidiary CanSino Shanghai signed a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines, targeting gastrointestinal solid tumors and rare tumor indications, covering the full chain from early R&D to commercialization. CLSA noted in a research report that CANSINOBIO's mRNA development route and antigen design are broadly comparable to Moderna's, representing a platform-level valuation re-rating opportunity. Additionally, BOCOM International highlighted that mainland China's mRNA vaccine industry remains severely undervalued, with Moderna's melanoma Phase III study reaching its primary endpoint potentially driving sector-wide valuation recovery.

Meanwhile, the company reported strong first-half results with revenue of RMB 550 million, up 43.81% year-on-year, and overseas revenue surging 4,724% to RMB 152 million, underscoring its expanding international footprint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)